588-63-6

Basic information

• Product Name: 3-Phenoxypropyl bromide
• Synonyms: PHENYL 3-BROMOPROPYL ETHER;(3-bromopropoxy)-benzen;Ether, 3-bromopropyl phenyl;gamma-Phenoxypropyl bromide;ISOPROPYL 3-BROMOPHENYL KETONE;BENZENE, (3-BROMOPROPOXY)-;3-PHENOXYBROMOPROPANE;3-PHENOXYPROPYL BROMIDE
• CAS NO: 588-63-6
• Molecular Formula: C₉H₁₁BrO
• Molecular Weight: 215.09
• EINECS: 209-623-4
• Product Categories: Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds;Building Blocks;C9;Chemical Synthesis;Ethers;Organic Building Blocks;Oxygen Compounds
• Mol File: 588-63-6.mol
• Article Data: 48

Chemical Properties

• Melting Point: 10-11 °C(lit.)
• Boiling Point: 222 °C(lit.)
• Flash Point: 228 °F
• Appearance: Clear slightly brown/Liquid
• Density: 1.365 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0184mmHg at 25°C
• Refractive Index: n20/D 1.546(lit.)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, DMSO (Slightly), Methanol (Slightly)
• BRN: 508978
• CAS DataBase Reference: 3-Phenoxypropyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Phenoxypropyl bromide(588-63-6)
• EPA Substance Registry System: 3-Phenoxypropyl bromide(588-63-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-24/25
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 588-63-6(Hazardous Substances Data)

Usage

Chemical Properties

lightbrown liquid

Uses

3-Phenoxypropyl Bromide is a reagent used in the synthesis of damidines in the study of myotonic dystrophy. Also used in thepreparation pf phenoxyalkylbenzimidazoles with antitubercular activity.

InChI:InChI=1/C9H11BrO/c10-7-4-8-11-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2

Upstream product

• 57334-32-4 3-phenoxypropyl-4-methylbenzene sulfonate 
• 2364-59-2 γ-phenoxybutyric acid ethyl ester 
• 6303-58-8 4-phenyloxybutanoic acid 
• 66003-76-7 Diphenyliodonium triflate 
• 627-18-9 1-bromo-3-propanol 
• 109-64-8 1,3-dibromo-propane 
• 108-95-2 phenol 
• 6180-61-6 3-phenoxypropanol 
• 3229-70-7 phenolate 
• 506-68-3 bromocyane 
• 32599-03-4 1-(3-phenoxypropyl)piperidine 
• 109-70-6 1.3-chlorobromopropane 
• 7497-87-2 1-bromo-4-(3'-bromopropoxy)benzene 
• 1746-13-0 allyl phenyl ether 

Downstream Products

• 35672-06-1 4-((3R)-4c-ethyl-5-oxo-tetrahydro-furan-3r-ylmethyl)-3-methyl-1-(3-phenoxy-propyl)-imidazolium; bromide 
• 183062-09-1 bis-(3-phenoxy-propyl)-amine 
• 116871-22-8 1-Methyl-4-(3-phenoxy-propyl)-piperazine 
• 66291-15-4 (3-nitro-propyl)-phenyl ether 
• 65670-71-5 C₂₅H₂₅N₃O₄S 
• 14122-36-2 2-(3-Phenoxy-propyl)-isothiourea 
• 62806-51-3 Diethyl-thiocarbamic acid S-(3-phenoxy-propyl) ester 
• 62806-50-2 S-3-(phenoxy)propyl-N,N-dimethylthiolcarbamate 
• 60706-42-5 Thiocarbamidsaeure-S-<3-phenoxy-propylester> 
• 53874-01-4 1-[2-Hydroxy-6-(3-phenoxy-propoxy)-phenyl]-ethanone 
• 7617-76-7 3-phenoxypropanamine 
• 10125-18-5 1,6-diphenoxyhexane 
• 20549-68-2 1-(3-iodopropoxy)benzene 
• 6303-58-8 4-phenyloxybutanoic acid 

Relevant articles and documents

Preparation method 3 - phenoxybromopropane or analogue thereof

The invention discloses a preparation method of 3 -phenoxybromopropane or an analogue thereof, wherein 3 - phenoxybromopropane and an allyl compound thereof are obtained through substitution reaction and addition reaction so as to avoid the inconvenience of using gaseous hydrogen bromide, 2nd-step addition reaction is realized by using the brominated salt and the acid in situ, and the process is simple in operation. The condition is easy to control, the atom economy is good, the aspect of environmental impact is low pollution, zero emission accords with the current green chemical synthesis direction, and the cost is economic.

Development of Membrane-Active Honokiol/Magnolol Amphiphiles as Potent Antibacterial Agents against Methicillin-Resistant Staphylococcus aureus (MRSA)

Currently, infections caused by drug-resistant bacteria have become a new challenge in anti-infective treatment, seriously endangering public health. In our continuous effort to develop new antimicrobials, a series of novel honokiol/magnolol amphiphiles were prepared by mimicking the chemical structures and antibacterial properties of cationic antimicrobial peptides. Among them, compound 5i showed excellent antibacterial activity against Gram-positive bacteria and clinical MRSA isolates (minimum inhibitory concentrations (MICs) = 0.5-2 μg/mL) with low hemolytic and cytotoxic activities and high membrane selectivity. Moreover, 5i exhibited rapid bactericidal properties, low resistance frequency, and good capabilities of disrupting bacterial biofilms. Mechanism studies revealed that 5i destroyed bacterial cell membranes, resulting in bacterial death. Additionally, 5i displayed high biosafety and potent in vivo anti-infective potency in a murine sepsis model. Our study indicates that these honokiol/magnolol amphiphiles shed light on developing novel antibacterial agents, and 5i is a potential antibacterial candidate for combating MRSA infections.

Synthesis of Medium-Ring-Sized Benzolactams by Using Strong Electrophiles and Quantitative Evaluation of Ring-Size Dependency of the Cyclization Reaction Rate

Benzolactams with medium-sized rings were synthesized via the electrophilic aromatic substitution reaction of carbamoyl cations (R1R2N+═C═O) in good to high yields without dilution. These reactions were utilized to quantitatively examine the extent of retardation of medium-sized ring formation, compared to five- or six-membered ring formation. The order of reaction rates of formation of cyclic benzolactams is six- > five- > seven- > eight- > nine-membered ring at 25 °C. The present reaction provides a route to eight- A nd nine-membered benzolactams.